Pyxis Oncology Earnings Call Transcripts
Fiscal Year 2025
-
MCVO demonstrated strong preliminary efficacy and manageable safety in both monotherapy and combination with pembrolizumab for recurrent/metastatic head and neck cancer, with high response and disease control rates across diverse patient backgrounds. Adjusted Ideal Body Weight dosing is being implemented to further optimize safety, and pivotal studies are planned with FDA alignment.
-
The lead ADC asset demonstrated strong efficacy and safety in early trials, especially in head and neck cancer, with broad tumor regression and durable responses. Expansion trials target key resistant populations and combination strategies, with year-end data expected to inform competitive positioning and regulatory plans.
-
MICVO, a non-internalizing ADC, is advancing in head and neck cancer with promising phase I results, including a 50% response rate and strong tolerability. Upcoming Q4 data will cover both monotherapy and combination cohorts, aiming to meet or exceed a 35% ORR benchmark in a competitive landscape.
-
MICO, an ADC targeting EDB, is prioritized for head and neck cancer with monotherapy and combination trials, aiming for key data readouts in the next 12 months. Early efficacy and safety data are promising, and the company is well-funded through upcoming catalysts.
-
MICVO, an extracellular targeting ADC, is showing strong efficacy in head and neck cancer, especially in heavily pretreated patients, with a favorable safety profile and broad applicability across subgroups. Upcoming data from expansion cohorts and combination studies with pembrolizumab will further define its competitive positioning.
-
MICVO, an extracellular targeting ADC, showed a 50% ORR in heavily pretreated head and neck cancer patients with a strong safety profile. Key data readouts for monotherapy and combo studies are expected in 2H 2024 and 1H 2025, with ongoing translational research and a solid cash runway.
-
MICVO, a novel ADC, has shown promising tumor regression and disease control across multiple tumor types, with a particularly strong signal in head and neck cancer. Safety profile is favorable, and upcoming data from expanded monotherapy and combination trials are expected to further validate efficacy and broaden clinical potential.
-
A single-asset strategy is underway, focusing on MICVO, an extracellular ADC showing strong efficacy and safety in head and neck cancer. Mechanistic innovation is validated by recent scientific advances, and upcoming data will further clarify its clinical potential.
-
PYX-201, a novel ADC targeting EDB in the tumor microenvironment, showed strong safety and promising efficacy, especially in head and neck cancer, with durable responses and activity in EGFR-refractory patients. Expansion and combination studies are underway, with key data expected later this year.
Fiscal Year 2024
-
PYX-201, a novel ADC, showed strong safety and efficacy in late-stage cancers, especially head and neck, with a 50% response rate and durable benefit. Promising activity was also seen in five other tumor types. Three head and neck studies and a Merck collaboration are launching soon.
-
Three clinical-stage assets are advancing, with PYX-201 leading in a phase I basket trial targeting tumor stroma. Data readouts for PYX-201 and PYX-106 are expected by year-end, guiding future development and indication selection. Cash reserves support operations through 2026.
-
The company is advancing a first-in-class ADC targeting tumor stroma, with strong clinical interest and promising early safety and efficacy signals. A major data release this fall will guide next steps, with a solid cash runway through 2026 and a focus on monotherapy before exploring combinations.